Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 125 от 222

Набира участници

Eating Disorders Genetics Initiative 2

Anorexia Nervosa Bulimia Nervosa Binge-Eating Disorder Avoidant Restrictive Food Intake Disorder

The overarching intention of the Eating Disorder Genetics Initiative 2 (EDGI2) is to increase sample size, diversity, and eating disorder phenotypes. The investigators are enrolling 20,000 new participants with anorexia nervosa (AN), bulimia nervosa (BN), binge-eating disorder (BED), avoidant/restrictive food intake disorder (ARFID), and controls in the US, Mexico, Australia, New Zealand, Sweden, and Denmark. A primary study goal is to enroll at least 30% of participants from underrepresented groups. Participants are asked to complete a series of questionnaires and submit a saliva sample for genotyping. The goal is to better understand eating disorders and how they relate to each other so that better treatments can be developed.

Начало: 28.10.2024 Край: 01.08.2027 Възраст: 12–99 г.

Australia, Mexico, New Zealand +2 University of North Carolina, Chapel Hill NCT06594913

Набира участници

ATHNdataset Registry

Hemophilia Thrombosis Hemophilia A Hemophilia B +5

The Hemophilia Treatment Center (HTC) where you receive care is working with The American Thrombosis and Hemostasis Network (ATHN) to look at the quality of life of people with blood disorders and problems. Doctors, scientists, policymakers, and other health care providers need a large amount of information from a lot of people to answer scientific, public health, and policy questions about better ways to treat blood disorders. They will use the information from the ATHNdataset to answer these questions.

Начало: 25.10.2024 Край: 31.10.2055

United States American Thrombosis and Hemostasis Network NCT06820515

Набира участници Фаза 3

MDMA-assisted Massed Prolonged Exposure for PTSD

Post-Traumatic Stress Disorder

The overall objective of this study is to pilot the VASDHS-adapted Emory MDMA-PE Protocol (aE-MDMA-PE) and assess the effect on clinician-rated PTSD symptoms in veterans who receive different doses of MDMA.

Начало: 25.10.2024 Край: 31.08.2027 Възраст: 18–64 г.

United States Healing Breakthrough NCT06117306

Набира участници Фаза 1/2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

Advanced Cancer Advanced Solid Tumors

This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK201. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK201 as a monotherapy in adult participants with Advanced Solid Tumors. The study will also identify recommended dose(s) for subsequent clinical studies of ALK201.

Начало: 24.10.2024 Край: 22.04.2028 Възраст: 18–75 г. Лечение

Australia, China Shanghai Allink Biotherapeutics Co., Ltd. NCT06656390

Набира участници Фаза 1/2

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

Healthy Volunteers, Pulmonary Arterial Hypertension

A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)

Начало: 24.10.2024 Край: 31.12.2028 Възраст: 18–100 г. Лечение

Australia, Brazil, Czechia +9 Novartis Pharmaceuticals NCT06649110

Набира участници Фаза 1

A Study of DM001 in Patients With Advanced Solid Tumors

Breast Neoplasms Carcinoma, Non-Small-Cell Lung Solid Carcinoma

The goal of this clinical trial is to find out about the safety, efficacy, and tolerability of DM001 for patients with the advanced solid tumors. DM001 is an experimental drug which is not approved by health authorities for the treatment of advanced solid tumors. Participants will have up to 17 visits during the study.There will be up to a 4-week Screening Period followed by a treatment period that will be divided into 3-week cycles/ Participants will have 5 study visits during Cycle 1, 3 visits during Cycles 2 and 3, and 1 visit during subsequent cycles. Participants will have an End of Treatment visit 21 days (+ 7 days) after last dose of study drug and then a follow-up visit 30 days (± 7 days) after the End of Treatment visit.

Начало: 24.10.2024 Край: 13.02.2027 Възраст: от 18 г. Лечение

Australia, United States Xadcera Biopharmaceutical (Suzhou) Co., Ltd. NCT06475937

Набира участници Фаза 3

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Classic Follicular Lymphoma Follicular Lymphoma With Unusual Cytological Features

This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.

Начало: 23.10.2024 Край: 31.03.2032 Възраст: от 18 г.

United States National Cancer Institute (NCI) NCT06337318

Набира участници Фаза 2

Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Follicular Lymphoma

This is a Phase 2, multicenter study evaluating the efficacy and safety of mosunetuzumab + zanubrutinib (M+Z) used as salvage strategy in patients with R/R FL who have received at least one line of prior systemic therapy.

Начало: 23.10.2024 Край: 15.09.2033 Възраст: от 18 г. Лечение

Australia, Italy Fondazione Italiana Linfomi - ETS NCT06492837

Набира участници

Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders

Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including Sickle Cell Disease Cystic Fibrosis Fragile X Syndrome +11

Cell-free fetal DNA (cffDNA) is present in the maternal blood from the early first trimester of gestation and makes up 5%-20% of the total circulating cell-free DNA (cfDNA) in maternal plasma. Its presence in maternal plasma has allowed development of noninvasive prenatal diagnosis for single-gene disorders (SGD-NIPD). This can be performed from 9 weeks of amenorrhea and offers an early, safe and accurate definitive diagnosis without the miscarriage risk associated with invasive procedures. One of the major difficulties is distinguishing fetal genotype in the high background of maternal cfDNA, which leads to several technical and analytical challenges. Besides, unlike noninvasive prenatal testing for aneuploidy, NIPD for monogenic diseases represent a smaller market opportunity, and many cases must be provided on a bespoke, patient- or disease-specific basis. As a result, implementation of SGD-NIPD remained sparse, with most testing being delivered in a research setting. The present project aims to take advantage of the unique French collaborative network to make SGD-NIPD possible for theoretically any monogenic disorder and any family.

Начало: 23.10.2024 Край: 01.05.2027 Възраст: от 18 г.

France Assistance Publique - Hôpitaux de Paris NCT06147414

Набира участници

INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use

Systemic Lupus Erythematosus (SLE)

INTERSTELLAR study will generate critical prospective real-world evidence on the benefits of adding Anifrolumab to standard of care treatment for SLE in routine clinical practice, to inform physicians, payers and patients. The study will use clinical assessments that are relevant for SLE-treating physicians in routine clinical practice, as well as introduce a specific measure for skin manifestations to affirm the potency of anifrolumab in treating SLE-related skin manifestations. The study will use standardized objectives, inclusion/exclusion criteria and outcome measures across all countries participating in this study including GCC (Qatar, KSA), Mexico, CAMCAR (Costa Rica, Panama, Dominican Republic), Colombia, Argentina, Taiwan, and Egypt, and any other countries that may be included in the study, in order to facilitate a comparison and analysis across all countries included in this study.

Начало: 22.10.2024 Край: 30.04.2027 Възраст: от 18 г.

Kazakhstan AstraZeneca NCT06314282

Набира участници Фаза 2

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

Basal Ganglia Germinoma Diabetes Insipidus Germinoma Pineal Region Germinoma +2

This phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin \& Etoposide) works in treating children with central nervous system (CNS) germinomas. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Researchers want to see if lowering the dose of standard radiotherapy (RT) after chemotherapy can help get rid of CNS germinomas with fewer long-term side effects.

Начало: 22.10.2024 Край: 04.11.2033 Възраст: 3–29 г. Лечение

Australia, Canada, United States Children's Oncology Group NCT06368817

Набира участници Фаза 3

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Metastatic Castration-Resistant Prostate Cancer

This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.

Начало: 22.10.2024 Край: 30.11.2028 Възраст: от 18 г. Лечение

Argentina, Brazil, Bulgaria +23 Pfizer NCT06629779

Набира участници Фаза 3

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment. The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus enzalutamide versus physician's choice of enzalutamide or docetaxel.

Начало: 21.10.2024 Край: 29.10.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +20 Pfizer NCT06551324

Набира участници Фаза 3

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

Long COVID Sars-CoV-2 Infection Coronavirus Infections COVID-19

The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomarkers of inflammation and viral measures, in participants with Long COVID.

Начало: 21.10.2024 Край: 01.07.2027 Възраст: от 18 г.

United States Wes Ely NCT06631287

Набира участници Фаза 2

A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

Idiopathic Short Stature

The purpose of this study is to evaluate i) the effect of multiple doses of vosoritide and ii) the effect of the therapeutic dose of vosoritide compared to human growth hormone (hGH)(hGH; only in the United States), in children with idiopathic short stature (ISS).

Начало: 21.10.2024 Край: 01.12.2036 Възраст: 3–11 г. Лечение

Australia, France, Germany +3 BioMarin Pharmaceutical NCT06382155

Набира участници

Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors

High-risk Neuroblastoma

The study participant is being asked to be in a research study called LEGACY, because you were treated for high-risk neuroblastoma (HR-NBL). Primary Objective To determine the feasibility of conducting comprehensive evaluations, leveraging the established SJLIFE (St. Jude Lifetime Cohort Study) study infrastructure, in survivors of HR-NBL (high-risk neuroblastoma) who are greater than 2 years from completion of contemporary therapy and were previously treated at SJCRH (St. Jude Children's Research Hospital). Exploratory Objectives * To describe the health outcomes of survivors of HR-NBL previously treated at SJCRH with contemporary era therapy who are greater than 2 years from completion of therapy. * To describe the relationship between patient outcomes and social determinants of health (SDOH) in survivors of HR-NBL previously treated at SJCRH with contemporary era therapy who are greater than 2 years from completion of therapy.

Начало: 21.10.2024 Край: 01.12.2028 Възраст: от 5 г.

United States St. Jude Children's Research Hospital NCT06480526

Набира участници Фаза 3

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Carcinoma, Non-Small-Cell Lung

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).

Начало: 21.10.2024 Край: 26.01.2038 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +28 Merck Sharp & Dohme LLC NCT06623422

Набира участници

NeoDoppler: New Ultrasound Technology for Continuous Monitoring of Cerebral Circulation Pilot

Preterm Patent Ductus Arteriosus Sepsis Asphyxia +3

Non-invasive tools for monitoring of course of disease are important and necessary in the treatment of pre-term/premature infants and sick neonates. For many years, the ultrasound group in Trondheim has been at the forefront in the development of new ultrasound technology for the diagnosis and monitoring of disease. Several methods previously developed in this research group are today widely used in hospitals around the world. In this project the investigators aim to test a new ultrasound technology that allows continuous monitoring of cerebral blood flow in sick neonates and pre-term children. This technology was CE-certified in October 2022, and in this project the investigators will test the CE-certified version with the newest available approved software.

Начало: 20.10.2024 Край: 31.12.2029 Възраст: до 12 г.

Norway St. Olavs Hospital NCT06646250

Набира участници Фаза 3

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)

The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV, respectively during the double-blinded treatment period (DBTP). At the end of the treatment period (up to 24 weeks), all participants will receive efgartigimod IV during the first 52-week open-label treatment period (OLTP1). At the end of the first OLTP1, participants may begin a second 52-week OLTP2. After the OLTP2, the participants will enter a follow-up period (approximately 8 weeks) while off study drug. The participants will be in the study for up to 138 weeks. More information can be found here: https://clinicaltrials.argenx.com/advancenext

Начало: 18.10.2024 Край: 01.06.2028 Възраст: от 18 г.

Austria, Bulgaria, China +14 argenx NCT06544499

Набира участници Фаза 1

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

Advanced Solid Tumor

This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in participants with advanced solid tumors.

Начало: 18.10.2024 Край: 30.09.2028 Възраст: от 18 г. Лечение

Australia, China, South Korea +1 BeiGene NCT06598800

1 … 123 124 125 126 127 … 222